Physician profile
Sharee D Besson
NPI 1942626783
$3,550.08
in general payments reported to CMS, 2019-2025
41 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,255 · 2022: $697 · 2023: $898 · 2024: $295 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,249 · Travel and Lodging: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,248.60 |
| Travel and Lodging | $349.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $535.36 | 2021-2025 | |
| Relievant Medsystems, INC. | $487.17 | 2023 | Intracept |
| Collegium Pharmaceutical, INC. | $277.88 | 2022-2025 | Belbuca |
| Esperion Therapeutics, INC. | $192.95 | 2021-2022 | |
| Novo Nordisk INC | $177.52 | 2021-2022 | |
| Boston Scientific Corporation | $168.16 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Saluda Medical Americas, INC. | $163.58 | 2025 | Evoke |
| Glaxosmithkline, LLC. | $152.28 | 2021-2025 | Arexvy, Shingrix |
| Nevro Corp. | $133.81 | 2023 | Senza |
| Lilly USA, LLC | $132.18 | 2021-2022 | |
| Pfizer INC. | $107.21 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.01 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $77.30 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.65 | 2021-2022 | |
| Amgen INC. | $67.30 | 2021-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharee Besson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.